Muhammad Shahzeb Munir MD MPH, MS (He/Him)

Internal Medicine•Middleton, WI

Hospital Medicine/Hospitalist, Preventive Medicine

Principal Investigator

Join to View Full Profile

9419 Stoneywood BlvdMiddleton, WI 53562
Phone+1 510-821-2641

Summary

I am a full time Principal Investigator on Industry Sponsored Clinical Trials and a part time Internist / Hospitalist.

Clinical Expertise

General preventive medicine, Hospitalist medicine, Clinical research

Education & Training

Univeristy of WisconsinMS, Biotechnology, 2019 - 2021
Mayo Clinic College of Medicine and Science (Rochester)Residency, Public Health and General Preventive Medicine, 2011 - 2013
University of MinnesottaMPH, Public Health, 2011 - 2013
Wellspan Health/York HospitalResidency, Internal Medicine, 2008 - 2010
University of Maryland Medical Center Midtown CampusInternship, Internal Medicine, 2007 - 2008
University of Medicine and Pharmacy ‘Gr T Popa” Iasi Class of 2001

Certifications & Licensure

GA State Medical License 2022 - 2025
WI State Medical License 2013 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Preventive Medicine Public Health & General Preventive Medicine

Awards, Honors, & Recognition

Distinguished Service Award Preventive Medicine Residency Program, SMPH, UW Madison, 2018

Clinical Trials

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease Start of enrollment: 2022 Dec 29
RECRUITING
PHASE3
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older Start of enrollment: 2021 Jul 21
COMPLETED
PHASE3
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above Start of enrollment: 2021 May 25
COMPLETED
PHASE3
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 Start of enrollment: 2020 Dec 27
Completed
Phase 3
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older Start of enrollment: 2020 Aug 20
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis Start of enrollment: 2021 Feb 22
COMPLETED
PHASE3
Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) Start of enrollment: 2020 May 20
Completed
Phase 2, Phase 3
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE Start of enrollment: 2020 Sep 04
COMPLETED
PHASE4
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm Start of enrollment: 2020 May 02
Completed
Phase 3
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies Start of enrollment: 2021 Dec 15
COMPLETED
PHASE3
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Start of enrollment: 2023 Apr 17
COMPLETED
PHASE3
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age Start of enrollment: 2023 Oct 19
COMPLETED
PHASE3
Join now to see all

Publications & Presentations

PubMed

6 citations
Genetic Markers Associated With Plasma Protein C Level in African Americans: The Atherosclerosis Risk in Communities (ARIC) Study
M. Shahzeb Munir, Lu-Chen Weng, Weihong Tang, Saonli Basu, James S. Pankow
Genetic Epidemiology. 2014-12-01
13 citations
The association of 9p21-3 locus with coronary atherosclerosis: a systematic review and meta-analysis
Muhammad S Munir, Zhen Wang, Fares Alahdab, Mark W. Steffen, Patricia J. Erwin
BMC Medical Genetics. 2014-06-06
8 citations
Circadian Body Temperature Variability is an Indicator of Poor Prognosis in Cardiomyopathic Hamsters
Amany Ahmed, Sreedevi Gondi, Casey Cox, Suwei Wang, Igor V. Stupin
Journal of Cardiac Failure. 2010-03-01

Journal Articles

Effect of P2Y12 Inhibitors on Organ Support–Free Survival in Critically Ill Patients Hospitalized for COVID-19
ACTIV-4a Investigators, JAMA Network Open, 5/25/2023
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
The ATTACC, ACTIV-4a, and REMAP-CAP Investigators, N Engl J Med 2021; 385:790-802 DOI: 10.1056/NEJMoa2105911, 8/26/2021